Company BiomX Inc.

Equities

PHGE

US09090D1037

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nyse Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
0.3701 ^USD	-11.46%		-11.46%	+32.18%

May. 21	Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024
May. 20	BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Number of employees: 65

Managers	Title	Age	Since
Jonathan Solomon CEO	Chief Executive Officer	47	19-10-27
Anat Primovich IRC	Investor Relations Contact	-	21-09-30
Inbal Benjamini-Elran HRO	Human Resources Officer	-	19-12-31
Myriam Golembo PRN	Corporate Officer/Principal	59	19-10-30
Merav Bassan PRN	Corporate Officer/Principal	59	19-10-27
Assaf Oron PRN	Corporate Officer/Principal	49	19-10-27

Members of the board	Title	Age	Since
Russell Greig CHM	Chairman	71	19-10-27
Jonathan Solomon CEO	Chief Executive Officer	47	19-10-27
Edward Williams BRD	Director/Board Member	68	23-10-11
Alan Moses BRD	Director/Board Member	76	20-10-01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	69,806,440	48,574,052 ( 69.58 %)	0	69.58 %
Stock B	0	256,887	0	0

Name	Equities	%	Valuation
OrbiMed Advisors Private Equity 24.94 %	13,773,653	24.94 %	5 M $
Cystic Fibrosis Foundation 16.90 %	9,330,580	16.90 %	3 M $
Deerfield Management Co. LP (Private Equity) 11.06 %	6,110,098	11.06 %	2 M $
Nimble Partners LLC 8.240 %	4,550,000	8.240 %	2 M $
AMR Action Fund GP LLC 5.532 %	3,054,870	5.532 %	1 M $
Rodney Hodges 5.143 %	2,839,714	5.143 %	954 144 $
Johnson & Johnson Innovation - JJDC, Inc. 3.483 %	1,923,201	3.483 %	646 196 $
Eight Enterprises LLC 1.967 %	1,086,191	1.967 %	364 960 $
Chidozie Ugwumba 1.671 %	922,800	1.671 %	310 061 $
JSR CORPORATION 0.4527 %	250,000	0.4527 %	84 000 $

Name	Equities	%	Valuation
Walleye Capital LLC 0.0276 %	12,688	0.0276 %	4 035 $
Goldman Sachs & Co. LLC 0.0226 %	10,392	0.0226 %	3 305 $
UBS Securities LLC 0.000091 %	42	0.000091 %	13 $

BiomX, Inc.

22 Einstein Street Floor 4

7414003, Ness Ziona

http://www.biomx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3701 USD

Average target price

2.833 USD

Spread / Average Target

+665.56%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOMX INC.	+32.18%	29.18M
VERTEX PHARMACEUTICALS INCORPORATED	+19.33%	125B
REGENERON PHARMACEUTICALS, INC.	+13.95%	109B
BIONTECH SE	-3.53%	24.74B
ARGENX SE	+2.71%	22.67B
GENMAB A/S	-9.95%	18.14B
WUXI APPTEC CO., LTD.	-41.48%	16.67B
BEIGENE, LTD.	-12.62%	16.64B
NEUROCRINE BIOSCIENCES, INC.	+0.99%	13.45B
SAREPTA THERAPEUTICS, INC.	+21.79%	11.32B

Bio Therapeutic Drugs